At a glance
- Originator Merck & Co
- Class Antihyperglycaemics
- Mechanism of Action Somatostatin receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetes mellitus
Most Recent Events
- 13 Jun 2001 No-Development-Reported for Diabetes mellitus in USA (Unknown route)
- 09 Sep 1998 New profile
- 09 Sep 1998 Preclinical development for Diabetes mellitus in USA (Unknown route)